Abstract
Diabetes mellitus is an important comorbidity in patients with heart failure. The presence of heart failure in diabetes worsens the prognosis of patients. Recent studies suggest that appropriate diagnostic approaches followed by differential medical treatment are of crucial importance to improve patient outcomes. This article summarizes important aspects of the association between diabetes mellitus and heart failure.
Zusammenfassung
Diabetes mellitus stellt eine bedeutende Komorbidität bei Patienten mit Herzinsuffizienz dar. Durch das Vorliegen einer Herzinsuffizienz bei Diabetes mellitus verschlechtert sich die Prognose der Patienten. Um die Ergebnisse für die Patienten zu verbessern, sind aktuellen Studien zufolge entsprechend geeignete diagnostische Ansätze und daran anschließend eine differenzierte medizinische Behandlung von entscheidender Bedeutung. In dem vorliegenden Beitrag werden wichtige Aspekte des Zusammenhangs zwischen Diabetes mellitus und Herzinsuffizienz zusammengefasst.
Similar content being viewed by others
Abbreviations
- ACE:
-
Angiotensin-converting enzyme
- ARB:
-
Angiotensin II receptor blockers
- ARNI:
-
Angiotensin receptor-neprilysin inhibitor
- BNP:
-
Brain-type natriuretic peptide
- CANVAS:
-
Canagliflozin Cardiovascular Assessment Study
- CARMELINA:
-
The Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus
- CAROLINA:
-
Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes
- CHARM:
-
Candesartan in Heart Failure—Assessment of Reduction in Mortality and Morbidity
- COPD:
-
Chronic obstructive pulmonary disease
- CRT:
-
Cardiac resynchronization therapy
- CV:
-
Cardiovascular
- DECLARE TIMI 58:
-
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
- DIAMOND:
-
Danish Investigations of Arrhythmia and Mortality on Dofetilide
- DPP-4:
-
Dipeptidyl peptidase-4
- ECG:
-
Electrocardiography
- EMPA-REG Outcome:
-
Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients
- EXAMINE:
-
Cardiovascular Outcomes Study of Alogliptin in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- GIP:
-
Glucose-dependent insulinotropic peptide
- GLP-1:
-
Glucagon-like peptide 1
- HARMONY:
-
Effect of Albiglutide, When Added to Standard Blood Glucose-Lowering Therapies, on Major Cardiovascular Events in Subjects with Type 2 Diabetes Mellitus
- HFmrEF:
-
Heart failure mid-range ejection fraction
- HFpEF:
-
Heart failure with preserved ejection fraction
- HFrEF:
-
Heart failure with reduced ejection fraction
- ICD:
-
Implantable cardioverter defibrillator
- LAVI:
-
Left atrial volume index
- LEADER:
-
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes Results
- LVEF:
-
Left ventricular ejection fraction
- LVMI:
-
Left ventricular mass index
- MRA:
-
Mineralocorticoid receptor antagonists
- MRI:
-
Magnetic resonance imaging
- NT-proBNP:
-
N-terminal pro-brain natriuretic peptide
- NYHA:
-
New York Heart Association
- ORIGIN:
-
Outcome Reduction with Initial Glargine Intervention
- PARADIGM-HF:
-
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction
- SAVOR-TIMI 53:
-
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
- SGLT2:
-
Sodium-dependent glucose transporter
- SUSTAIN 6:
-
A Long-Term, Randomised, Double-Blind, Placebo-Controlled, Multinational, Multi-Centre Trial to Evaluate Cardiovascular and Other Long-Term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN™ 6: Long-Term Outcomes)
- TECOS:
-
A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control
- UKPDS:
-
The UK Prospective Diabetes Study
- VALIANT:
-
Valsartan in Acute Myocardial Infarction trial
References
Aguilar D, Chan W, Bozkurt B et al (2011) Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 4:53–58
Aguilar D, Solomon SD, Kober L et al (2004) Newly diagnosed and previously known diabetes mellitus and 1‑year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 110:1572–1578
Anonymous (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853
Bahrami H, Bluemke DA, Kronmal R et al (2008) Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 51:1775–1783
Cavender MA, White WB, Jarolim P et al (2017) Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial (examination of cardiovascular outcomes with Alogliptin versus standard of care). Circulation 135:1911–1921
Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289
Erdmann E, Charbonnel B, Wilcox RG et al (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30:2773–2778
Fitchett D, Zinman B, Wanner C et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 37:1526–1534
Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328
Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242
Gustafsson I, Brendorp B, Seibaek M et al (2004) Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 43:771–777
Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519–1529
Kristensen SL, Preiss D, Jhund PS et al (2016) Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. https://doi.org/10.1161/circheartfailure.115.002560
Lehrke M, Marx N (2011) Cardiovascular effects of incretin-based therapies. Rev Diabet Stud 8:382–391
Macdonald MR, Petrie MC, Varyani F et al (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:1377–1385
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322
Marx N, Mcguire DK (2016) Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 37:3192. https://doi.org/10.1093/eurheartj/ehw110
Marx N, Rosenstock J, Kahn SE et al (2015) Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(R)). Diab Vasc Dis Res 12:164–174
Mcallister DA, Read SH, Kerssens J et al (2018) Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. Circulation 138:2774–2786
Mcguire DK, Alexander JH, Johansen OE et al (2018) Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation 139:351. https://doi.org/10.1161/circulationaha.118.038352
Mcguire DK, Van De Werf Armstrong FPW et al (2016) Association between Sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 1:126–135
Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657
Nichols GA, Gullion CM, Koro CE et al (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884
Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975
Rosenstock J, Perkovic V, Johansen OE et al (2018) Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2018.18269
Rubler S, Dlugash J, Yuceoglu YZ et al (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602
Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326
Scirica BM, Braunwald E, Raz I et al (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130:1579–1588
Wanner C, Marx N (2018) SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia 61:2134–2139
White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357
Zelniker TA, Wiviott SD, Raz I et al (2018) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. https://doi.org/10.1016/s0140-6736(18)32590-x
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117
Zannad F, Cannon CP, Cushman WC et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385(9982):2067–2076
Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247–2257
Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228–1239
Roumie CL, Min JY, D’Agostino McGowan L et al (2017) Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study. J Am Heart Assoc. https://doi.org/10.1161/JAHA.116.005379
Holman RR, Coleman RL, Chan JCN et al (2017) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 5(11):877–886
Chiasson JL, Josse RG, Gomis R et al (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290(4):486–494
Packer M (2018) Is metformin beneficial for heart failure in patients with type 2 diabetes? Diabetes Res Clin Pract 136:168–170
Crowley MJ, Diamantidis CJ, McDuffie JR et al (2017) Clinical outcomes of Metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 166(3):191–200
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
K. Schütt declares the following: speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, MSD, Novo Nordisk, OmniaMed; research grant from Boehringer Ingelheim; advisory board member of Amgen, Boehringer Ingelheim. N. Marx declares the following: speaker fees from Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, Lilly, NovoNordisk, Bayer; research grant from Boehringer Ingelheim; advisory board member of Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, NovoNordisk. N. Marx declines all personal compensation from pharmaceutical or medical device companies.
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Schütt, K., Marx, N. Heart failure and diabetes: management and open issues. Herz 44, 203–209 (2019). https://doi.org/10.1007/s00059-019-4792-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00059-019-4792-9